TYRA · CIK 0001863127
What Tyra Biosciences, Inc. told the SEC could break it.
Tyra Biosciences' disclosures are those of a pre-revenue biotech reliant on outside money and outside manufacturing. It has no commercial revenue, posted a $119.9M net loss in 2025 against a $371.3M accumulated deficit, and must keep raising capital to fund development. It owns no manufacturing and relies entirely on third parties to make its product candidates for preclinical and clinical work, which risks shortfalls in supply or acceptable cost. Some of those contract manufacturers are in China, exposing it to U.S. legislation, sanctions, tariffs, and trade restrictions that could raise costs or reduce the supply of material available to it.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- pre-revenue with $371.3M accumulated deficit; dependent on additional financingmedium
Tyra has no commercial revenue, posted a $119.9M net loss in 2025 and a $371.3M accumulated deficit, and must continue to rely on additional financing.
“Our net losses were $119.9 million and $86.5 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $371.3 million.”
SEC filing →As of 2026
Regulatory & policy
- China contract manufacturers exposed to tariffs/sanctions/trade restrictionsmedium
Tyra relies on contract manufacturers in China that may be subject to U.S. legislation, sanctions, tariffs and trade restrictions, raising cost or reducing supply.
“we currently and may in the future rely on contract manufacturers in China. Such foreign contract manufacturers may be subject to U.S. legislation, sanctions, tariffs, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us”
Supplier concentration
- full reliance on third-party manufacturers (no in-house manufacturing)medium
Tyra has no manufacturing of its own and relies entirely on third parties to make its product candidates for preclinical and clinical development.
“We rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could dela”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch